PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
0.00 - 0.01
0.00 - 0.02
289 / 496.9K (Avg.)
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
187.83%
Positive revenue growth while ECL.AX is negative. John Neff might see a notable competitive edge here.
141.82%
Gross profit growth above 1.5x ECL.AX's 2.26%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
1131.48%
Positive EBIT growth while ECL.AX is negative. John Neff might see a substantial edge in operational management.
1131.48%
Positive operating income growth while ECL.AX is negative. John Neff might view this as a competitive edge in operations.
682.71%
Positive net income growth while ECL.AX is negative. John Neff might see a big relative performance advantage.
500.00%
Positive EPS growth while ECL.AX is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
500.00%
Positive diluted EPS growth while ECL.AX is negative. John Neff might view this as a strong relative advantage in controlling dilution.
-3.85%
Both firms reduce share counts. Martin Whitman would compare buyback intensity relative to free cash flow generation.
-2.97%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
No Data
No Data available this quarter, please select a different quarter.
-1723.26%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-4204.46%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
-31.83%
Both companies have negative long-term revenue/share growth. Martin Whitman would question if the entire market or product set is shrinking.
221.27%
5Y revenue/share CAGR above 1.5x ECL.AX's 69.39%. David Dodd would look for consistent product or market expansions fueling outperformance.
105.69%
3Y revenue/share CAGR above 1.5x ECL.AX's 67.55%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
-277.17%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-424.53%
Negative 5Y OCF/share CAGR while ECL.AX is at 123.80%. Joel Greenblatt would question the firm’s operational model or cost structure.
-668.10%
Negative 3Y OCF/share CAGR while ECL.AX stands at 703.65%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
408.00%
Similar net income/share CAGR to ECL.AX's 405.70%. Walter Schloss would see parallel tailwinds or expansions for both firms.
500.00%
5Y net income/share CAGR above 1.5x ECL.AX's 19.60%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
60.00%
3Y net income/share CAGR 1.25-1.5x ECL.AX's 51.59%. Bruce Berkowitz might see new markets, M&A, or better cost discipline driving the difference.
No Data
No Data available this quarter, please select a different quarter.
1831.22%
5Y equity/share CAGR above 1.5x ECL.AX's 1.09%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
116.58%
3Y equity/share CAGR above 1.5x ECL.AX's 15.72%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
219.76%
Our AR growth while ECL.AX is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
-7.99%
Inventory is declining while ECL.AX stands at 4.26%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
28.58%
Asset growth above 1.5x ECL.AX's 6.10%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
27.93%
BV/share growth above 1.5x ECL.AX's 2.05%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
51.86%
Debt shrinking faster vs. ECL.AX's 5350.00%. David Dodd sees a safer balance sheet if it doesn't impair future growth.
-100.00%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
15.25%
We expand SG&A while ECL.AX cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.